ERBB2 and inflammatory breast carcinoma: Our results from this systematic review support these findings; specifically, subgroup analysis showed the highest weighted-average pCR rate (54.3%, 95% CI, 44.3%-64.0%) for anti-HER2 therapy (trastuzumab and lapatinib) in the HER2-positive IBC subgroup, and a weighted-average pCR rate of only 20.2% (95% CI 14.4%-27.1%) for other targeted therapies (bevacizumab, panitumumab, and tipifarnib) in IBC patients.